



Date: October 1, 2009

For Release: Immediately

Refer to: Eli Lilly and Company: Carole Puls, 317.277.1421
VIANEX: Mr Panos Tsitsios, +30 210 8009312

Lilly Transfers Capastat[®] License and Trademark to VIANEX S.A.

VIANEX to acquire rights to manufacture, market and distribute drug in Europe

INDIANAPOLIS/ATHENS – Eli Lilly and Company (NYSE: LLY) and VIANEX S.A. today announced an agreement in which Lilly will transfer its Spanish license and trademark for Capastat[®] Sulfate (capreomycin for injection, USP) to VIANEX. VIANEX also will receive Lilly's rights to the Capastat trademark in other European markets.

VIANEX, a pharmaceutical company in Greece, will acquire Lilly's rights to manufacture, market and distribute Capastat in Europe. VIANEX expects to launch the product by the end of 2010. Financial terms of the agreement were not disclosed.

Capastat is one of two Lilly medicines used to treat multidrug-resistant (MDR) TB. In 2003, Lilly launched The Lilly MDR-TB Partnership, a public-private affiliation of 20 organizations dedicated to eradicating MDR-TB. Through this Partnership, Lilly is transferring the manufacturing technology for these two medicines to manufacturers who either operate in some of the countries hardest-hit by MDR-TB, or offer unique capabilities to help ensure availability of these medicines at lower costs.



“We are happy to collaborate with Lilly on the MDR-TB program and to assist Lilly on the global philanthropic work they have undertaken in order to improve the lives of patients with MDR-TB,” said Paul Giannacopoulos, CEO of VIANEX S.A.

As a key partner in The Lilly MDR-TB Partnership, VIANEX also will work with international organizations to ensure supply of the medicine globally.

“Lilly is pleased to continue our long-standing partnership with VIANEX to help increase the capacity for Capastat production globally in order to meet growing patient demand,” said Iain Richardson, senior director of Lilly’s global supply chain. “With drug resistance at an all-time high, and patient numbers growing dramatically from year to year, the need to effectively treat MDR-TB is more important now than ever.”

More information about the Lilly MDR-TB Partnership is available at www.lillymdr-tb.com.

###

About Lilly

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About VIANEX S.A.

Vianex S.A., established in 1924, is the leading Greek pharmaceutical company involved in the manufacturing, licensing, marketing and distribution of pharmaceutical products, Rx and OTCs. Its four state-of-the-art, fully specialized manufacturing plants, all EGMP approved, offer manufacturing capabilities for all pharmaceutical forms and products, including injectables, solid forms, lyophilized and cytotoxics and cephalosporins in dedicated plants.